Current options to manage Waldenström’s macroglobulinemia
- 25 May 2017
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Hematology
- Vol. 10 (7), 637-647
- https://doi.org/10.1080/17474086.2017.1339596
Abstract
Introduction: Waldenström’s macroglobulinemia (WM) is a rare, incurable B-cell lymphoma, with a median survival of 5–10 years in symptomatic patients. There is no consensus on the standard of care and several agents are currently used in these patients. Areas covered: In this article, we will review the use of standard therapies and new drugs investigated such as monoclonal antibodies, proteasome inhibitors, immunomodulatory agents, Bruton’s tyrosine kinase inhibitors and novel agents in early-stage development. Expert commentary: RCD (Rituximab/Cyclophosphamide/Dexamethasone) is an effective and safe treatment in first line in WM. BR (Bendamustine/Rituximab) or BRD (Bortezomib/Rituximab/Dexamethasone) provide durable responses, and are still indicated in most patients. Ibrutinib is a new option and it was approved as primary therapy and for relapse. Carfilzomib based therapy represents an emerging option for proteasome-inhibitor based therapy for WM. Despite encouraging results, WM remains an incurable disease; therefore, new treatment options are needed. For this reason, continued participation in clinical trials should be encouraged.Keywords
This publication has 58 references indexed in Scilit:
- MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activityBritish Journal of Haematology, 2015
- Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2015
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusBlood, 2014
- Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemiaBlood, 2014
- Temporal and geographic variations of Waldenstrom macroglobulinemia incidenceCancer, 2011
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood, 2011
- Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in SwedenBlood, 2008
- Waldenström macroglobulinemiaBlood, 2007
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's MacroglobulinemiaBlood, 2006
- Characterization of familial Waldenström's macroglobulinemiaAnnals of Oncology, 2005